


CYN 154806 TFA

Cat. No.:	HY-P1202A
Molecular Formula:	C ₅₈ H ₆₉ F ₃ N ₁₂ O ₁₆ S ₂
Molecular Weight:	1311.36
Sequence:	Ac-Phe(4-NO ₂)-Cys-Tyr-Trp-Lys-Thr-Cys-Tyr-NH ₂ (Disulfide bridge: Cys2-Cys7)
Sequence Shortening:	Ac-F(4-NO ₂)CYWKTCY-NH ₂ (Disulfide bridge: Cys2-Cys7)
Target:	Somatostatin Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Sealed storage, away from moisture
	Powder -80°C 2 years
	-20°C 1 year



* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro

H₂O : 25 mg/mL (19.06 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
	1 mM		0.7626 mL	3.8128 mL	7.6257 mL
	5 mM		0.1525 mL	0.7626 mL	1.5251 mL
	10 mM		0.0763 mL	0.3813 mL	0.7626 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

CYN 154806 TFA, a cyclic octapeptide, is a potent and selective somatostatin sst2 receptor antagonist, with pIC₅₀ values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively^{[1][2]}.

IC₅₀ & Target

Somatostatin Receptor^[1]

In Vitro

CYN 154806 TFA inhibits SRIF-induced increases in extracellular acidification (EAR) in CHO-K1 cells expressing human sst2 receptors (pKB 7.92). CYN 154806 TFA also blocks SRIF-induced increases [35S]-GTPγS binding in CHO-K1 cell membranes expressing human sst2 receptors as well as rat sst2(a) and rat sst2(b) receptors (pKB 7.81, 7.68 and 7.96, respectively)^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

CYN 154806 TFA (0.1 mg/kg; i.p.; 20 min before the administration of carbachol (CCh) (30 μg/kg) in M4 KO mice) dose-dependently and significantly reverses the decreases acid response to CCh in M4 but not M3 KO mice^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Bass RT, et al. Identification and characterization of novel somatostatin antagonists. *Mol Pharmacol*. 1996 Oct;50(4):709-15.
- [2]. Feniuk W, et al. Selective somatostatin sst(2) receptor blockade with the novel cyclic octapeptide, CYN-154806. *Neuropharmacology*. 2000 Jun 8;39(8):1443-50.
- [3]. Takeuchi K, et al. Activation of Muscarinic Acetylcholine Receptor Subtype 4 Is Essential for Cholinergic Stimulation of Gastric Acid Secretion: Relation to D Cell/Somatostatin. *Front Pharmacol*. 2016 Aug 30;7:278.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA